Fujifilm doubles down on ex-Biogen facility with $928M infusion as biotech boom fuels CDMO growth
Almost a year after bagging a Biogen manufacturing subsidiary in Denmark for $890 million, Fujifilm is investing even more — to the tune of $928 million — to ramp up its biologics production capacity there.
Fujifilm Diosynth, the contract development and manufacturing arm of the Japanese conglomerate, has been steadily staking out its global presence in the past few years. In 2017 the focus was on expanding the monoclonal antibody facilities. The year after it ventured into regenerative medicine by buying up two companies specializing in cell culture media. Most recently it opened a gene therapy center in preparation for a new wave of treatments.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.